Sanofi $SNY Shares Bought by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. boosted its position in Sanofi (NASDAQ:SNY) by 7.2% in the third quarter, Holdings Channel.com reports. The firm owned 179,209 shares of the company’s stock after acquiring an additional 11,965 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Sanofi were worth $8,459,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Financial Consulate Inc. purchased a new stake in shares of Sanofi in the third quarter valued at approximately $26,000. Ameritas Advisory Services LLC acquired a new stake in Sanofi in the second quarter valued at $28,000. First Horizon Corp purchased a new stake in shares of Sanofi during the 3rd quarter worth $33,000. Salomon & Ludwin LLC grew its stake in shares of Sanofi by 1,046.3% during the 3rd quarter. Salomon & Ludwin LLC now owns 768 shares of the company’s stock worth $39,000 after purchasing an additional 701 shares during the period. Finally, Concord Wealth Partners increased its holdings in shares of Sanofi by 510.3% in the 2nd quarter. Concord Wealth Partners now owns 885 shares of the company’s stock valued at $43,000 after purchasing an additional 740 shares in the last quarter. Institutional investors and hedge funds own 14.03% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on SNY. HSBC restated a “buy” rating on shares of Sanofi in a research report on Wednesday, December 10th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Sanofi in a research note on Friday, January 16th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Sanofi in a research note on Monday, December 29th. Barclays downgraded Sanofi from an “overweight” rating to an “equal weight” rating in a research report on Tuesday, January 6th. Finally, Guggenheim cut Sanofi from a “buy” rating to a “neutral” rating in a research report on Tuesday, December 9th. Five research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $62.67.

Sanofi Trading Up 0.7%

Shares of Sanofi stock opened at $48.63 on Wednesday. Sanofi has a fifty-two week low of $44.62 and a fifty-two week high of $60.12. The business’s fifty day moving average is $47.85 and its two-hundred day moving average is $48.63. The company has a quick ratio of 0.29, a current ratio of 1.09 and a debt-to-equity ratio of 0.20. The firm has a market cap of $118.61 billion, a PE ratio of 13.51, a P/E/G ratio of 1.25 and a beta of 0.45.

Sanofi Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.